Opinion

Video

Patient Selection and Switching Patients to Subcutaneous Infliximab

Jean-Frederic Colombel, MD, examines considerations for transitioning patients from intravenous to subcutaneous infliximab and evaluates the role of subcutaneous infliximab within the evolving landscape of inflammatory bowel disease treatments.

  1. For patients currently receiving IV infliximab (originator or biosimilar), are there any considerations for switching them to subcutaneous infliximab?
  2. How will subcutaneous infliximab fit in with the growing IBD treatment landscape?
Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
4 experts are featured in this series.
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
© 2025 MJH Life Sciences

All rights reserved.